Youpei E. Lin

Key Laboratory Of Carcinogenesis And Cancer Invasion Of Ministry Of Education
Zhongshan, 200032, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications

Targeting MUC16 suppresses malignant progression and chemoresistance in large-duct type intrahepatic cholangiocarcinoma.

Targeting MUC16 suppresses malignant progression and chemoresistance in large-duct type intrahepatic cholangiocarcinoma.

Journal: Cancer letters
Published: November 10, 2025

Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma.

Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma.

Journal: Cancer discovery
Published: October 19, 2025

Robust transcriptomic hallmarks targeting intratumor heterogeneity in intrahepatic cholangiocarcinoma.

Robust transcriptomic hallmarks targeting intratumor heterogeneity in intrahepatic cholangiocarcinoma.

Journal: Cell reports. Medicine
Published: July 18, 2025

Harnessing alternative splicing for off-the-shelf mRNA neoantigen vaccines in hepatocellular carcinoma.

Harnessing alternative splicing for off-the-shelf mRNA neoantigen vaccines in hepatocellular carcinoma.

Journal: Cell research
Published: May 29, 2025

Exploration of multi-omics liquid biopsy approaches for multi-cancer early detection: The PROMISE study.

Exploration of multi-omics liquid biopsy approaches for multi-cancer early detection: The PROMISE study.

Journal: Innovation (Cambridge (Mass.))
Published: January 19, 2025

Integrated Multi-Omics Profiling Identifies PDZ-Binding Kinase (PBK) as a Novel Prognostic Biomarker in Hepatocellular Carcinoma.

Integrated Multi-Omics Profiling Identifies PDZ-Binding Kinase (PBK) as a Novel Prognostic Biomarker in Hepatocellular Carcinoma.

Journal: Journal of hepatocellular carcinoma
Published: August 30, 2024

AGEs-RAGE manipulates tumor intrinsic pERK/Sp1/IL6 pathway and reprograms macrophage to promote intrahepatic cholangiocarcinoma progression.

AGEs-RAGE manipulates tumor intrinsic pERK/Sp1/IL6 pathway and reprograms macrophage to promote intrahepatic cholangiocarcinoma progression.

Journal: Translational oncology
Published: June 28, 2024

Identification and validation of a lactate metabolism-related six-gene prognostic signature in intrahepatic cholangiocarcinoma.

Identification and validation of a lactate metabolism-related six-gene prognostic signature in intrahepatic cholangiocarcinoma.

Journal: Journal of cancer research and clinical oncology
Published: February 27, 2024

Stromal architecture and fibroblast subpopulations with opposing effects on outcomes in hepatocellular carcinoma.

Stromal architecture and fibroblast subpopulations with opposing effects on outcomes in hepatocellular carcinoma.

Journal: Cell discovery
Published: January 22, 2024

Whole-Genome DNA Methylation Profiling of Intrahepatic Cholangiocarcinoma Reveals Prognostic Subtypes with Distinct Biological Drivers.

Whole-Genome DNA Methylation Profiling of Intrahepatic Cholangiocarcinoma Reveals Prognostic Subtypes with Distinct Biological Drivers.

Journal: Cancer research
Published: October 23, 2023

Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology.

Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology.

Journal: Science translational medicine
Published: July 26, 2023

Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy.

Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy.

Journal: Cancer biology & medicine
Published: March 27, 2023
Showing 1-12 of 27

Last Updated: 09/26/2026